Ovarian Cancer Chemoresistance Analysis via Network Pharmacology

A 12.6 KB DOCX file presents a multiomics study on reversing chemoresistance in ovarian cancer. The research by Xin Hong integrates transcriptomics, network pharmacology, and machine learning to identify 26 overlapping gene targets and a seven-hub-gene predictive signature. It includes clinical cytokine profiling and in vitro validation data.

Use Cases

• Analyze the 26 overlapping gene targets to understand shared pathways in chemoresistant versus chemosensitive ovarian cancer subtypes.
• Validate the seven-hub-gene predictive signature for patient stratification into chemoresistant (Subtype 1) and chemosensitive (Subtype 2) subgroups.
• Examine clinical cytokine data to investigate the localized immunosuppressive tumor microenvironment.
• Use molecular docking scores, such as the SSZ–TNF binding affinity of -6.99 kcal/mol, for computational drug-target validation.

Strengths

• Study integrates multiple analytical methods: transcriptomics, network pharmacology, consensus clustering, machine learning, and molecular docking.
• Identifies a specific seven-hub-gene predictive signature for patient classification.
• Includes validation from in vitro drug sensitivity assays and clinical cytokine profiling.

Limitations

• The dataset is a 12.6 KB DOCX document, not a structured data table, limiting direct computational analysis.
• No raw transcriptomics data, column definitions, or sample data are provided within the file.
• The clinical scope and sample size of the supporting data are not specified.

Provenance

Source

figshare, author Xin Hong.

Collection Method

Multiomics strategy applied to transcriptomics from resistant and sensitive ovarian cancer models.

Time Range

null

Freshness

Last updated March 26, 2026.

Geography

null